Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant

Immunobiology

Volumn 218, Issue 12, 2013, Pages 1468-1476

  Engel, Abbi L ^a   Sun, Guan Cheng ^a   Gad, Ekram ^b   Rastetter, Lauren R ^b   Strobe, Katie ^a   Yang, Yi ^b   Dang, Yushe ^b   Disis, Mary L ^b   Lu, Hailing ^b  

^a BASTYR UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Dendritic cells; OVA peptide; PSK; Vaccine

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERBACEOUS AGENT; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23P19; INTERLEUKIN 6; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; OVALBUMIN; P 323 339; PROTEIN BOUND POLYSACCHARIDE K; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CELL ACTIVATION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; EX VIVO STUDY; FEMALE; GENE EXPRESSION; IMMUNOSTIMULATION; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TRAMETES VERSICOLOR; VACCINATION;

BMDC; BONE MARROW-DERIVED DC; CAM; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CFSE; COMPLEMENTARY AND ALTERNATIVE MEDICINE; CTL; CYTOTOXIC T LYMPHOCYTE; DC; DENDRITIC CELLS; FBS; FETAL BOVINE SERUM; GM-CSF; GRANULOCYTES MACROPHAGES-COLONY STIMULATING FACTOR; IFN-Γ; IL; INTERFERON GAMMA; INTERLEUKIN; MAB; MONOCLONAL ANTIBODY; OVA; OVA PEPTIDE; OVALBUMIN; PATTERN RECOGNITION RECEPTORS; PBS; PHOSPHATE BUFFERED SALINE; PROTEIN-BOUND POLYSACCHARIDE-K (KUREHA); PRR; PSK; TLR; TNF-Α; TOLL-LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; OVALBUMIN; PEPTIDE FRAGMENTS; PROTEOGLYCANS; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TRAMETES; UP-REGULATION; VACCINES, SUBUNIT;

EID: 84885901277     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2013.05.001     Document Type: Article

References (44)

1. Aguilar J.C., Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25:3752-3762.
2. Aliahmadi E., Gramlich R., Grutzkau A., Hitzler M., Kruger M., Baumgrass R., Schreiner M., Wittig B., Wanner R., Peiser M. TLR2-activated human Langerhans cells promote Th17 polarization via IL-1beta, TGF-beta and IL-23. Eur. J. Immunol. 2009, 39:1221-1230.
3. Asprodites N., Zheng L., Geng D., Velasco-Gonzalez C., Sanchez-Perez L., Davila E. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J. 2008, 22:3628-3637.
4. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
5. + T lymphocytes by immune-stimulating complexes in vivo. Int. Immunol. 2003, 15:711-720.
6. Brown G.D., Taylor P.R., Reid D.M., Willment J.A., Williams D.L., Martinez-Pomares L., Wong S.Y., Gordon S. Dectin-1 is a major beta-glucan receptor on macrophages. J. Exp. Med. 2002, 196:407-412.
7. Brown G.D., Herre J., Williams D.L., Willment J.A., Marshall A.S., Gordon S. Dectin-1 mediates the biological effects of beta-glucans. J. Exp. Med. 2003, 197:1119-1124.
8. Cheng C., Jain P., Bettahi I., Pal S., Tifrea D., de la Maza L.M. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine 2011, 29:6641-6649.
9. Cheng K.F., Leung P.C. General review of polysaccharopeptides (PSP) from C. versicolor: pharmacological and clinical studies. Cancer Ther. 2008, 6:117-130.
10. + T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2. J. Immunol. 2011, 187:1692-1701.
11. Dang Y., Wagner W.M., Gad E., Rastetter L., Berger C.M., Holt G.E., Disis M.L. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin. Cancer Res. 2012, 18:3122-3131.
12. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., Hoff S.T., Andersen P., Reed S.G., Morris S.L., Roederer M., Seder R.A. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 2007, 13:843-850.
13. Dearman R.J., Cumberbatch M., Maxwell G., Basketter D.A., Kimber I. Toll-like receptor ligand activation of murine bone marrow-derived dendritic cells. Immunology 2009, 126:475-484.
14. Engel A.L., Holt G.E., Lu H. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev. Clin. Pharmacol. 2011, 4:275-289.
15. Hennessy E.J., Parker A.E., O'Neill L.A. Targeting Toll-like receptors: emerging therapeutics?. Nat. Rev. Drug Discov. 2010, 9:293-307.
16. Honda-Okubo Y., Saade F., Petrovsky N. Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 2012, 30:5373-5381.
17. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S., Hartmann G. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168:4531-4537.
18. Huang H., Ostroff G.R., Lee C.K., Wang J.P., Specht C.A., Levitz S.M. Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and Toll-like receptor agonists. Infect. Immun. 2009, 77:1774-1781.
19. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., Smith C., Zeng W., Brown L.E. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15440-15445.
20. Joffre O., Nolte M.A., Sporri R., Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 2009, 227:234-247.
21. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., Liu Y.J. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001, 194:863-869.
22. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007, 13:552-559.
23. Lu H., Knutson K.L., Gad E., Disis M.L. The tumor antigen repertoire identified in tumor-bearing Neu transgenic mice predicts human tumor antigens. Cancer Res. 2006, 66:9754-9761.
24. Lu H., Wagner W.M., Gad E., Yang Y., Duan H., Amon L.M., Van Denend N., Larson E.R., Chang A., Tufvesson H., Disis M.L. Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J. Immunol. 2010, 184:5360-5367.
25. Lu H., Yang Y., Gad E., Inatsuka C., Wenner C.A., Disis M.L., Standish L.J. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin. Cancer Res. 2011, 17:6742-6753.
26. Lu H., Yang Y., Gad E., Wenner C.A., Chang A., Larson E.R., Dang Y., Martzen M., Standish L.J., Disis M.L. Polysaccharide Krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin. Cancer Res. 2011, 17:67-76.
27. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., Hatton R.D., Wahl S.M., Schoeb T.R., Weaver C.T. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234.
28. McDonnell A.M., Robinson B.W., Currie A.J. Tumor antigen cross-presentation and the dendritic cell: where it all begins?. Clin. Dev. Immunol. 2010, 2010:539519-539520.
29. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
30. Mercier B.C., Cottalorda A., Coupet C.A., Marvel J., Bonnefoy-Berard N. TLR2 engagement on CD8 T cells enables generation of functional memory cells in response to a suboptimal TCR signal. J. Immunol. 2009, 182:1860-1867.
31. Muzio M., Bosisio D., Polentarutti N., D'Amico G., Stoppacciaro A., Mancinelli R., van't Veer C., Penton-Rol G., Ruco L.P., Allavena P., Mantovani A. Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 2000, 164:5998-6004.
32. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 2005, 6:769-776.
33. Oba K., Teramukai S., Kobayashi M., Matsui T., Kodera Y., Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol. Immunother. 2007, 56:905-911.
34. Ohwada S., Ikeya T., Yokomori T., Kusaba T., Roppongi T., Takahashi T., Nakamura S., Kakinuma S., Iwazaki S., Ishikawa H., Kawate S., Nakajima T., Morishita Y. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br. J. Cancer 2004, 90:1003-1010.
35. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 2012, 12:265-277.
36. Park K.H., Gad E., Goodell V., Dang Y., Wild T., Higgins D., Fintak P., Childs J., Dela Rosa C., Disis M.L. Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res. 2008, 68:8400-8409.
37. Perona-Wright G., Jenkins S.J., O'Connor R.A., Zienkiewicz D., McSorley H.J., Maizels R.M., Anderton S.M., MacDonald A.S. A pivotal role for CD40-mediated IL-6 production by dendritic cells during IL-17 induction in vivo. J. Immunol. 2009, 182:2808-2815.
38. Ragupathi G., Yeung K.S., Leung P.C., Lee M., Lau C.B., Vickers A., Hood C., Deng G., Cheung N.K., Cassileth B., Livingston P. Evaluation of widely consumed botanicals as immunological adjuvants. Vaccine 2008, 26:4860-4865.
39. Sakamoto J., Morita S., Oba K., Matsui T., Kobayashi M., Nakazato H., Ohashi Y. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol. Immunother. 2006, 55:404-411.
40. Schmid M.A., Takizawa H., Baumjohann D.R., Saito Y., Manz M.G. Bone marrow dendritic cell progenitors sense pathogens via Toll-like receptors and subsequently migrate to inflamed lymph nodes. Blood 2011, 118:4829-4840.
41. Tritto E., Mosca F., De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009, 27:3331-3334.
42. Yokoe T., Iino Y., Takei H., Horiguchi J., Koibuchi Y., Maemura M., Ohwada S., Morishita Y. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Anticancer Res. 1997, 17:2815-2818.
43. Yuan J., Gnjatic S., Li H., Powel S., Gallardo H.F., Ritter E., Ku G.Y., Jungbluth A.A., Segal N.H., Rasalan T.S., Manukian G., Xu Y., Roman R.A., Terzulli S.L., Heywood M., Pogoriler E., Ritter G., Old L.J., Allison J.P., Wolchok J.D. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20410-20415.
44. Zeng W., Azzopardi K., Hocking D., Wong C.Y., Robevska G., Tauschek M., Robins-Browne R.M., Jackson D.C. A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli. Vaccine 2012, 30:4800-4806.